Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 April 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

High death rate with irinotecan, fluorouracil, and leucovorin for colorectal cancer

Due to the potential importance in the treatment of colorectal cancer, a letter to the editor of the New England Journal of Medicine on the safety of a chemotherapy regime has been released before its publication date.

News image

fiogf49gjkf04

The final version of the letter will be published on June 21.

The authors have reported an unexpectedly high rate of death associated with the combination of irinotecan, fluorouracil, and leucovorin, used for treatment of colorectal cancer, in two separate studies.

Both trials are currently being performed throughout the United States and Canada.

The first study is being conducted on patients with metastatic colon cancer. In this trial, the regimen of irinotecan, fluorouracil, and leucovorin is being compared with a regimen of oxaliplatin, fluorouracil, and leucovorin, and a regimen of oxaliplatin and irinotecan.

12 of the 14 deaths in the group assigned to the regimen of irinotecan, fluorouracil, and leucovorin had several characteristics in common. These were dehydration (resulting from diarrhea, nausea, and vomiting), neutropenia, and sepsis, leading to death.

13 of the 14 deaths were found to occur during the first 6-week cycle of chemotherapy or immediately afterward.

The second adjuvant study involving patients with resected stage III colon cancer, is comparing fluorouracil and leucovorin with the irinotecan, fluorouracil, and leucovorin regimen.

14 deaths have been reported in the group assigned to receive triple therapy. The causes of these were pulmonary emboli (in 3 patients); sepsis (3); aspiration (3); myocardial infarction (1); dehydration and neutropenia (1); a cerebrovascular accident (1); bowel ischemia, infarct, or both (1); and unknown (1).

Clinical factors that increase mortality risk from the regimen have not been identified.
N Engl J Med

On the basis of these data the researchers have recommended the suspension of both trials.

In each trial, dose modifications were made in an attempt to ameliorate the toxic effects of the regimen.

Daniel J. Sargent, of the Mayo Clinic, Rochester, Minnesota, and fellow authors comment, "Vigilant monitoring of all patients who are receiving this combination of irinotecan, fluorouracil, and leucovorin is called for because specific clinical factors that increase the risk of adverse effects have not yet been identified."

"The regimen has been shown to improve survival in patients with advanced colorectal cancer. Combination therapy with irinotecan, fluorouracil, and leucovorin should continue to be an option in this treatment setting, but in our experience has been associated with an excessive rate of early deaths," they conclude.

Patients concerned about these findings will be reading further reports from CNN, MSNBC, and the Washington Post.

N Engl J Med May 17, 2001
21 May 2001

Go to top of page Email this page Email this page to a colleague

 20 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 20 April 2018 
Obesity and physical activity in diverticulosis
 20 April 2018 
Worldwide H.pylori prevalence
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
Fibrosis in patients with chronic hepatitis B
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA
 18 April 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 18 April 2018 
Hep C treatment for sustained virologic response
 18 April 2018 
Endoscopic necrosectomy reduces risk of death 
 17 April 2018 
Colorectal cancer screening and ethnic inequities
 17 April 2018 
Training programs should consider radiation education for advanced endoscopy fellows
 17 April 2018 
Aspirin and pancreatic cancer
 16 April 2018 
Surgery for colorectal polyps has increased 
 16 April 2018 
Advanced fibrosis can be ruled out in primary health care patients
 16 April 2018 
Antibiotic use and colorectal adenoma
 13 April 2018 
Colorectal cancer cell lines
 13 April 2018 
Infliximab and corticosteroid-free clinical remission in Crohn's
 13 April 2018 
Teduglutide for children with short bowel syndrome
 12 April 2018 
Prescriptions for opiate drugs amongst primary care patients with IBD
 12 April 2018 
Lower GI bleeding related to comorbidity
 12 April 2018 
non–Clostridium difficile bacterial infections in IBD
 11 April 2018 
Physician perception of IBD trial results
 11 April 2018 
Bile acid deficiency in IBS 
 11 April 2018 
Stem cell therapy for fistulas in Crohn's
 10 April 2018 
Overweight in childhood and type 2 diabetes
 10 April 2018 
immunoglobulin G associates with clinical features of IBD
 10 April 2018 
T-cells repertoires in celiac disease
 09 April 2018 
Biomarker tests for colorectal cancer screening
 09 April 2018 
Fecal transplantation in C. difficile infection and treatment outcome 
 09 April 2018 
No weigh-loss drug improved all cardiometabolic risk factors
 06 April 2018 
Colonoscopy and colorectal cancer mortality
 06 April 2018 
Eosinophilic esophagitis and health-related quality of life
 06 April 2018 
Microbiome in athletes vs sedentary subjects
 05 April 2018 
Laparoscopic Nissen fundoplication for GERD treatment
 05 April 2018 
Random biopsies for neoplasia in IBD
 05 April 2018 
Scoring system identifies cancer risk in Barrett's
 04 April 2018 
Alpha‐1 antitrypsin deficiency and liver disease
 04 April 2018 
PPI and risk of stroke
 04 April 2018 
Adjuvant chemotherapy for advanced colon cancer
 29 March 2018 
Prevention of metachronous gastric cancer
 29 March 2018 
Acute lower GI bleeding
 28 March 2018 
Decision aid used by IBD patients
 28 March 2018 
Transition for young adults with IBD
 28 March 2018 
Amitriptyline in functional dyspepsia
 27 March 2018 
Emergency department utilization for IBD 
 27 March 2018 
Management of hemorrhoids in the USA
 27 March 2018 
Adult ulcerative colitis
 26 March 2018 
Biological therapy response in IBD 
 26 March 2018 
Obesity and diverticulosis
 26 March 2018 
Practice guidelines for chronic constipation
 23 March 2018 
Health-related quality of life in eosinophilic esophagitis
 23 March 2018 
Genetics and chronic liver disease
 23 March 2018 
Global prevalence of H.pylori
 22 March 2018 
H. pyloris and gastric cancer
 22 March 2018 
Pancreatitis after IBS treatment 
 22 March 2018 
Mechanisms of action in patients with IBS
 21 March 2018 
Panel markers for early detection of colon cancer

 21 March 2018 
Blood test differentiates celiac disease
 21 March 2018 
Patient characteristics and colonoscopy preparation

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us